Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Cantor Fitzgerald
US Army
Express Scripts
Baxter
Farmers Insurance
McKinsey
Citi
Johnson and Johnson

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,681,768

« Back to Dashboard

Which drugs does patent 6,681,768 protect, and when does it expire?

Patent 6,681,768 protects TUDORZA PRESSAIR and is included in one NDA.
Summary for Patent: 6,681,768
Title: Powder formulation disintegrating system and method for dry powder inhalers
Abstract:A disperser for dry powders which can be used with different dose systems, dose weights ranging from 2 to 25 mg and different types of powder formulation. In one embodiment, the disperser acts both as a de-agglomeration (disintegration; aerosolization) means and as an air classifier for especially adhesive mixtures. Only fine drug particles are emitted whereas the larger agglomerates and carrier crystals are retained by the disperser. Another embodiment enables time controlled release of carrier crystals in these mixtures. Yet another embodiment has optimized performance with spherical pellets, containing no carrier crystals. Other possible embodiments of the invention make it possible to control the total inhaler resistance and the powder deposition in the upper respiratory tract by means of the addition of a so-called sheath flow of clean air. Modifications also enable carrier retainment in the mouthpiece and elimination of the tangential flow component of the discharge cloud.
Inventor(s): Haaije de Boer; Anne (Drachten, NL), Frijlink; Henderik Willem (Eelde, NL), Gjaltema; Doetie (Oosterwolde, NL), Goede; Joachim (Hanau, DE), Hagedoorn; Paul (Assen, NL)
Assignee: Sofotec GmbH & Co. KG (Frankfurt am Main, DE)
Application Number:10/177,433
Patent Claim Types:
see list of patent claims
Delivery;

Drugs Protected by US Patent 6,681,768

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Pharms TUDORZA PRESSAIR aclidinium bromide POWDER, METERED;INHALATION 202450-001 Jul 23, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
US Department of Justice
Dow
Teva
Cipla
Healthtrust
Moodys
Queensland Health
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.